Welcome to Medincell. Here we are committed to creating better medicines for all.
Impacting Global Health with Purposeful Innovation
Latest news & events
Improving health worldwide through new therapeutic options
Our talented team of international experts is committed to developing an innovative and diverse portfolio of breakthrough therapies.
Powered by proprietary cutting-edge long-acting injectable technology, we are redefining standards treatment efficiency and accessibility to enhance the quality of life for patients worldwide.
What is a long-acting injectable ?
In our commitment to advancing global health, we collaborate with leading pharmaceutical entities and foundations to introduce groundbreaking therapeutic solutions.
Key figures
1
FDA-approved best-in-class therapy based on our proprietary technology
2
potential first-in-class therapies in Phase 3 clinical trials
140
top-tier experts, all shareholders, steering our company's success
25
nationalities within our team, fostering a diverse and dynamic work environment
Products & R&D pipeline
At the core of our portfolio is a commitment to addressing critical medical challenges, aiming to profoundly impact not only patient lives but also society at large. Our innovative product candidates, rooted in our proprietary BEPO® long-acting injectable technology, are developed both in-house and in collaboration with leading international pharmaceutical firms and NGOs.
Products on market
Programs in clinical phase 3
mdc-TJK
In partnership with Teva Pharmaceuticals
Indication
Schizophrenia
Molecule
Olanzapine
Status
Clinical Phase 3
Technology
BEPO®
mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. It has the potential to be the first long-acting olanzapine with a favorable safety profile as other LAIs of olanzapine have an FDA black box warning for PDSS (Postinjection Delirium/Sedation Syndrome) that limits their use.
News related to the project
mdc-CWM
In partnership with AIC
Indication
Post-op pain
Molecule
Celecoxib
Status
Clinical Phase 3
Technology
BEPO®
Injected into the intra-articular space during Total Knee Replacement surgery and potentially active for as long as three months post-surgery, mdc-CWM is a sustained-release formulation of celecoxib for the reduction of postoperative pain and inflammation. The mdc-CWM project is a collaboration with Arthritis Innovation Corporation (AIC), based in Toronto, Canada, who finance and conduct the clinical development activities.
News related to the project
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
March 2025
Corporate presentation
Get in touch
Please use the form for any inquiries. We’ll get back to you promptly.
